Please login to the form below
CNS
This page shows the latest CNS news and features for those working in and with pharma, biotech and healthcare.
Roche to collaborate with Dyno on gene therapies for CNS/liver diseases
Swiss pharma giant Roche has partnered with Cambridge, Massachusetts-based Dyno Therapeutics for the development of gene therapies for central nervous system (CNS) and liver diseases. ... The companies will utilise Dyno’s CapsidMap platform to develop
Latest news
-
Stop that!
Stop that! Back to the strategy workshop. The clients, on a verge of a huge investment in CNS, wanted to anticipate the market but, still in a reductionist prison, was focused
-
AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
In addition, Tagrisso treatment also reduced the risk of CNS recurrence or death by 82%, although median CNS DFS was not reached yet in either arm of the study. ... According to AZ, CNS recurrence – in which the cancer spreads to the brain – is
-
Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout
This new collaboration with Tetra reinforces our steadfast commitment to advancing cutting-edge science in central nervous system (CNS) disorders including Alzheimer’s disease,” he added.
-
Nektar’s opioid analgesic slammed with FDA panel rejection
According to Nektar, NKTR-181 provides the same levels of pain relief as standard opioid products, but with reduced central nervous system (CNS) side-effects, namely euphoria.
-
Intra-Cellular soars on FDA approval of schizophrenia drug
According to Matteis, the Caplyta approval indicates that regulators will “often look at a mixed efficacy package in CNS through a 'glass half full lens'," due to the increased need for
More from news
Approximately 5 fully matching, plus 181 partially matching documents found.
Latest Intelligence
-
Gut instincts lead Takeda to GI pipeline success
that focused the company’s R&D strategy on cutting-edge, innovative approaches in GI, oncology and the central nervous system (CNS).
-
The search for treatments for Parkinson’s disease
CNS disease drug development is traditionally viewed as higher risk and more expensive,” added Dr Roach.” I do not have privileged internal information about Pfizer’s neurological programmes, but many big ... Pfizer is probably in that category, so
-
Rethinking trials: the pros and cons of protocol amendments
We typically see more amendments in oncology and CNS. We also see a higher incidence and average number of amendments in later stage phase 2 and 3 studies.
-
China’s clinical trial shake-up
These reporting rules require sponsors to upload information such as endpoints and eligibility criteria to www.chinadrugtrials.org.cn.
-
Key considerations for disease- modifying Parkinson’s disease trials
By Dr Peter Schueler, Senior Vice President, Drug Development Services and Haichen Yang, Vice President, Global Therapeutic Lead, both at CNS, ICON plc.
More from intelligence
Approximately 0 fully matching, plus 44 partially matching documents found.
Latest appointments
-
Ex-J&J exec Denice Torres joins bluebird bio’s board
During her time at J&J, Torres held several executive leadership roles including president of McNeil Consumer Healthcare and president of Janssen Pharmaceuticals, CNS.
-
New hires at FibroGen, Saniona and Turbine
He is a veteran biotech leader, with over 23 years of experience in rare diseases and CNS.
-
Axovant poaches Allergan’s and Teva’s chief medical and science officers
development. “We have a wonderful opportunity to develop life-changing medicines for patients with CNS diseases.
-
Damien McDevitt moves from GSK to Acadia Pharmaceuticals
At Acadia, which focuses on the development and commercialisation of medicines for central nervous system (CNS) disorders, McDevitt will report to the company’s president and chief executive officer Steve Davis. ... This expertise, combined with his
-
Ron Menezes joins Almirall’s Aqua Pharmaceuticals
Menezes joins the group from Depomed Pharmaceuticals, where he served as vice president of sales and sales operations, pain and CNS.
More from appointments
Approximately 0 fully matching, plus 27 partially matching documents found.
Latest from PMHub
-
Are patient recruitment and retention rates rising or falling?
in central nervous system (CNS) and oncology trials. ... CNS trial dropout rates grew to 25.9% from 19.2. Oncology trial rates grew to 19.3% from 18.2%.
-
New recommendations to stimulate braver and bolder communications
Lilianna Husseini, Director Communications, Oncology, Pfizer Global. Heidi LaPensée, Brand Lead, CNS, Sanofi UK.
-
Diagnosing the lag in neuropsychiatric treatments
Unlike the other organs in our body, the central nervous system (CNS) is surrounded by the Blood Brain Barrier (BBB). ... To say the BBB presents a formidable challenge in CNS drug development is an understatement.
-
Innovative approaches in the treatment of multiple sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. ... In the central nervous system (CNS, which includes the brain, optic nerves and spinal cord),
-
Innovative approaches in the treatment of multiple sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. ... In the central nervous system (CNS, which includes the brain, optic nerves and spinal cord),
More from PMHub
Approximately 0 fully matching, plus 11 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Account Director
-
Competitive
-
Medical Editor
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Senior Account Manager
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Nucleus Global announces a trio of promotions
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- PHE study finds people who have had COVID-19 can still transmit the virus
- CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers
- Pfizer introduces new logo in a ‘shift from commerce to science’
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
